Standout Papers

Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy 2006 2026 2012 2019 2.2k
  1. Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy (2006)
    Steven E. Kahn, Steven M. Haffner et al. New England Journal of Medicine

Immediate Impact

1 by Nobel laureates 14 from Science/Nature 118 standout
Sub-graph 1 of 17

Citing Papers

Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
2022 Standout
Pharmacological treatment of hyperglycemia in type 2 diabetes
2021 Standout
54 intermediate papers

Works of Mark O’Neill being referenced

Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy
2006 Standout
Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study
2005

Author Peers

Author Last Decade Papers Cites
Mark O’Neill 1289 1938 26 793 12 2.5k
Mark Heise 1928 2513 7 923 25 3.5k
Barbara G. Kravitz 1902 2378 8 894 23 3.5k
Glenn J. Gormley 531 1327 187 540 42 4.0k
M. Nauck 1097 2769 28 814 5 3.3k
Deborah A. Robins 941 1633 10 591 26 2.4k
Peter Stein 1196 1751 54 916 23 3.0k
Jeffrey I. Mechanick 376 2014 106 557 17 3.4k
Paul D. Rosenblit 853 2475 20 1270 31 3.6k
John Gerich 922 2433 20 912 11 3.0k
Sheldon J. Bleicher 893 1484 25 1115 26 3.5k

All Works

Loading papers...

Rankless by CCL
2026